Clinical Trial Consent Form (Pakistan)

A Clinical Trial Consent Form in Pakistan records the giver's informed consent to the act it covers and the limits placed on that permission.

The Drug Regulatory Authority of Pakistan (DRAP), established under the DRAP Act 2012, is the primary regulatory body for clinical trials of drugs, biologicals, and medical devices in Pakistan. DRAP's Good Clinical Practice (GCP) Guidelines, which align with the International Council for Harmonisation (ICH) E6(R2) guideline, require that informed consent be obtained from every participant before enrolment in a clinical trial, that the consent process be conducted by a qualified investigator, and that the consent form be reviewed and approved by an Institutional Review Board (IRB) or Ethics Review Committee (ERC) before use. DRAP must be notified of clinical trials and, for trials of new drugs, prior regulatory approval from DRAP's Drug Registration section is required under the Drugs Act 1976 (as supplemented by the DRAP Act 2012).

The National Bioethics Committee of Pakistan (NBC), established in 2004 under the Ministry of National Health Services, Regulations and Coordination, provides oversight of health research ethics and has published Pakistan-specific guidelines for health research, including requirements for informed consent that supplement DRAP's GCP requirements. Major research institutions in Pakistan — Aga Khan University (AKU) in Karachi, Shaukat Khanum Memorial Cancer Hospital in Lahore and Peshawar, Pakistan Institute of Medical Sciences (PIMS) in Islamabad, Jinnah Postgraduate Medical Centre (JPMC) in Karachi, and King Edward Medical University (KEMU) in Lahore — maintain their own Institutional Review Boards (IRBs) or Ethical Review Committees (ERCs) that review and approve clinical trial protocols and consent forms before a study may commence.

The Clinical Trial Consent Form in Pakistan must be written in a language the participant understands — typically both English and Urdu, as Urdu is the national language and the language most widely understood across Pakistan's diverse population. For participants from specific linguistic communities — Punjabi, Sindhi, Pashto, Balochi, or other regional languages — translation into the participant's primary language may be required to confirm genuine informed consent, particularly for rural populations with limited formal education.

Informed consent in Pakistan must satisfy the following requirements under DRAP GCP guidelines and the Declaration of Helsinki: the consent must be voluntary — free from coercion, undue influence, or inducement; the participant must be given adequate information about the study in language they can understand; the participant must have adequate time to consider their decision; the participant must have the opportunity to ask questions; the participant (or their legally authorised representative) must sign and date the consent form; an impartial witness must sign the form where the participant is unable to read; and the participant must receive a copy of the signed consent form.

The Contract Act 1872 (Act No. IX of 1872) provides the foundational legal framework for consent in Pakistan. Section 14 of the Contract Act 1872 defines free consent as consent not caused by coercion (Section 15), undue influence (Section 16), fraud (Section 17), misrepresentation (Section 18), or mistake. A Clinical Trial Consent Form must demonstrate that the participant's consent was freely given — investigators who withhold material risks or overstate benefits may be held liable for misrepresentation under Section 17 of the Contract Act 1872.

The Prevention of Electronic Crimes Act 2016 (PECA) and the Personal Data Protection Bill (pending enactment as of 2025) govern the protection of personal data collected during clinical trials. Participant data — medical histories, biological samples, genetic information — must be collected and stored in accordance with DRAP's GCP data protection requirements and the NBC's bioethics guidelines. Transfer of participant data outside Pakistan to a foreign sponsor requires compliance with SBP's foreign exchange regulations and DRAP's data transfer guidelines.

The Pakistan Medical and Dental Council (PMDC), now the Pakistan Medical Commission (PMC) established under the Pakistan Medical Commission Act 2020, regulates medical practitioners in Pakistan. Investigators conducting clinical trials must be PMC-registered physicians in good standing. The PMC's code of ethics requires physicians to obtain informed consent before any medical procedure, including experimental treatments — a Clinical Trial Consent Form signed by a qualified investigator provides evidence of compliance with the PMC's ethical standards.

The Higher Education Commission of Pakistan (HEC) regulates academic research conducted by universities. Medical universities affiliated with HEC — including the University of Health Sciences Lahore, Dow University of Health Sciences Karachi, and Khyber Medical University Peshawar — are required under HEC research ethics policy to maintain accredited IRBs and to require HEC-compliant consent forms for all human subjects research. The HEC also registers clinical research conducted by foreign pharmaceutical companies at Pakistani sites through its Research Ethics Guidelines.

A Clinical Trial Consent Form in Pakistan is required before enrolment of any participant in a clinical research study involving human subjects, without exception, as a non-negotiable ethical and regulatory requirement.

A Clinical Trial Consent Form is required when a pharmaceutical company — whether a multinational company such as GlaxoSmithKline Pakistan, Abbott Laboratories Pakistan, or Pfizer Pakistan, or a local generic manufacturer registered with DRAP — is conducting a Phase I, II, III, or IV clinical trial of a new drug, vaccine, biological, or medical device at a hospital or research centre in Pakistan, and must obtain DRAP regulatory approval and ethics committee approval before enrolment begins.

A Clinical Trial Consent Form is needed when a university research team at a Pakistani medical institution — Aga Khan University, University of Health Sciences Lahore, Dow University of Health Sciences Karachi, or any other HEC-recognized medical university — is conducting investigator-initiated research involving human participants, and must obtain IEC/IRB approval and participant consent before collecting any data or biological samples.

A Clinical Trial Consent Form is required when a public health research organisation — the Pakistan Medical Research Council (PMRC), the National Institute of Health (NIH) Islamabad, or a WHO-funded research programme — is conducting epidemiological studies, vaccine trials, or health intervention studies in Pakistani communities, requiring community-level consent processes alongside individual participant consent under the NBC's guidelines.

A Clinical Trial Consent Form is needed when a medical device company — local or international — is conducting a clinical evaluation study of a new medical device under DRAP's medical device regulations, requiring ethics committee approval and participant informed consent before implantation or testing of the device on human participants.

A Clinical Trial Consent Form is required when a hospital or research centre is conducting a study involving collection of biological samples (blood, tissue, genetic material) from patients or healthy volunteers for research purposes, even if the study does not involve an investigational drug or device — as biobank research and genetic research require separate informed consent under Pakistan's emerging bioethics framework and the NBC guidelines.

A Clinical Trial Consent Form is needed when a clinical trial involves a vulnerable population — children (requiring parental or guardian consent and, where appropriate, child assent under NBC guidelines), pregnant women, prisoners, persons with mental illness, or economically disadvantaged persons who may be vulnerable to undue inducement — where enhanced consent protections and additional ethics committee scrutiny are required under both DRAP GCP and the Declaration of Helsinki.

A Clinical Trial Consent Form is required when an international sponsor conducting a multi-country trial includes Pakistani sites — the consent form must comply with both the international sponsor's protocol requirements (typically ICH E6 GCP) and DRAP's local requirements, including the Urdu translation of the consent form reviewed and approved by the local IRB/ERC before enrolment commences.

A Clinical Trial Consent Form is needed when re-consent is required — for example, when the trial protocol is substantially amended in a way that affects participants' risks or the nature of their participation, when new safety information emerges requiring updated risk disclosure, or when the participant's circumstances change (such as onset of a new medical condition) that may affect their willingness to continue. DRAP GCP guidelines require re-consent in these circumstances, and the updated consent form must be reviewed by the IRB/ERC before use.

A valid Clinical Trial Consent Form in Pakistan under the DRAP Act 2012, ICH GCP E6(R2), and the Declaration of Helsinki must contain the following essential elements, as required by DRAP and by the institutional IRBs and ERCs of all major research institutions in Pakistan.

Study Title and Sponsor Identification: The full title of the clinical trial, the protocol number and version, the name and contact details of the principal investigator, the name of the sponsoring organisation (pharmaceutical company, research institution, government body), and the name of the institution where the trial is being conducted must appear on the first page of the consent form.

Purpose of the Research: A clear, lay-language explanation of the purpose of the study — what the research is trying to find out, why the participant has been invited to take part, and how many other participants will be enrolled in Pakistan and globally. This section must avoid technical jargon and must be reviewed by the IRB/ERC for comprehensibility.

Study Procedures: A step-by-step description of all procedures the participant will undergo — examinations, blood draws, medications to be administered, device applications, questionnaires, imaging studies, follow-up visits — including the frequency and duration of each procedure, the total time commitment required of the participant, and what distinguishes study procedures from routine clinical care.

Risks and Discomforts: A thorough, honest disclosure of all reasonably foreseeable risks and discomforts associated with participation — including known adverse effects of the investigational product, discomforts of study procedures (pain from blood draws, radiation from imaging), and risks to privacy from data collection. Under ICH GCP and the Declaration of Helsinki, risks must not be minimised or obscured. Under Section 17 of the Contract Act 1872, withholding known risks may constitute fraudulent misrepresentation vitiating the consent.

Benefits: A realistic statement of the potential benefits to the participant (if any) and to science and society. The consent form must not overstate benefits or create false therapeutic optimism — ICH GCP requires an objective assessment. Financial compensation for participation (if any) must be disclosed separately and must not constitute undue inducement under NBC guidelines.

Alternatives to Participation: A statement of alternative treatments or procedures available to the participant if they decline to participate in the trial, confirming that standard medical care will not be withheld or degraded if the participant declines. This reflects the principle in the Declaration of Helsinki that the best current treatment remains available to control group participants.

Confidentiality and Data Protection: The measures taken to protect the participant's personal data — anonymisation, pseudonymisation, encryption, restricted access — and who will have access to the participant's identifiable data (sponsor, DRAP inspectors, ethics committee, monitors). The DRAP's GCP data protection requirements, the Personal Data Protection Bill principles, and the NBC guidelines on data handling must all be addressed.

Voluntariness and Right to Withdraw: An explicit statement that participation is entirely voluntary, that the participant may withdraw at any time without penalty or loss of benefits to which they are otherwise entitled, and that withdrawal will not affect their medical care. Under Section 14 of the Contract Act 1872 and the Declaration of Helsinki Principle 22, this is a non-negotiable element of valid consent.

Contact Information: The name and 24-hour contact number of the principal investigator or their designated contact for research-related questions, the name and contact number of an independent person (not part of the research team) whom the participant can contact about their rights as a research participant, and the contact details of the IRB/ERC that reviewed and approved the study.

Signature Block: Separate signature lines for: the participant (or legally authorised representative, with their relationship to the participant stated); the investigator or authorised study staff member who conducted the consent discussion; and an impartial witness (required where the participant cannot read, signing to confirm the consent process was conducted appropriately and the participant appeared to give consent freely). All signatures must be accompanied by the date and the participant's CNIC number (or NICOP for foreign participants). The participant must receive a copy of the signed form.

Urdu Translation: DRAP GCP guidelines and NBC standards require the consent form to be available in Urdu for all participants who do not read English. The Urdu translation must be reviewed by the IRB/ERC for accuracy and must be certified by a qualified translator approved by the relevant research institution. For trials in Sindhi, Pashto, or Punjabi-speaking regions, additional regional language translations may be required by the local IRB.

Forms-legal.com provides this Clinical Trial Consent Form (Pakistan) template as a practical starting framework. Every clinical trial consent form must be reviewed and approved by the institution's IRB/ERC and by DRAP (for regulated clinical trials) before use — this template is a starting point for that process, not a substitute for ethics review. Research teams should also consult the National Bioethics Committee of Pakistan's published guidelines and the DRAP GCP Guidelines for Clinical Trials before finalising the consent documentation.